Quince Therapeutics, Inc. Stock

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
1.06 USD +2.91% Intraday chart for Quince Therapeutics, Inc. +0.95% +0.95%
Sales 2022 - Sales 2023 - Capitalization 45.01M 61.53M
Net income 2022 -51M -69.71M Net income 2023 -31M -42.37M EV / Sales 2022 -
Net cash position 2022 89.73M 123M Net cash position 2023 61.24M 83.72M EV / Sales 2023 -
P/E ratio 2022
-0.41 x
P/E ratio 2023
-1.25 x
Employees 32
Yield 2022 *
-
Yield 2023
-
Free-Float 82.94%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Quince Therapeutics, Inc.

1 day+2.91%
1 week+0.95%
1 month-6.19%
3 months-15.87%
6 months+4.95%
Current year+0.95%
More quotes
1 week
0.98
Extreme 0.98
1.12
1 month
0.89
Extreme 0.89
1.14
Current year
0.89
Extreme 0.89
1.43
1 year
0.84
Extreme 0.84
1.74
3 years
0.54
Extreme 0.5401
121.98
5 years
0.54
Extreme 0.5401
121.98
10 years
0.54
Extreme 0.5401
121.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 22-05-18
Director of Finance/CFO 39 22-04-30
President 60 23-08-31
Members of the board TitleAgeSince
Director/Board Member 82 18-02-28
Director/Board Member 63 23-10-22
Chief Executive Officer 54 22-05-18
More insiders
Date Price Change Volume
24-04-26 1.06 +2.91% 120,833
24-04-25 1.03 -2.83% 93,060
24-04-24 1.06 -4.50% 91,171
24-04-23 1.11 +4.72% 129,361
24-04-22 1.06 +0.95% 57,652

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. The Company’s asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.
More about the company